A66-22165-15069
2 vaccinations
1 coded response
20 check-ins
1 free-text entry
0 call cases
- Sex
- Female
- Age at first dose
- 26-30
- ZIP prefix
- 303 / GA
- Registered
- 2021-02-19
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-02-19
Registered in v-safe
-
2021-02-19
Dose 1 — Pfizer-BioNTech
- 2021-02-19
- 2021-02-20
- 2021-02-21
- 2021-02-22
- 2021-02-23
- 2021-02-24
- 2021-02-25
- 2021-02-26
- 2021-03-05
-
2021-03-12
Dose 2 — Pfizer-BioNTech
- 2021-03-12
-
2021-03-13
Survey response — days 1–6 daily, dose 2MedDRA: Presyncope, Tachycardia — Feeling: Poor · Headache, Fatigue or tiredness · Be unable to do your normal daily activitiesFree text: Tachycardia and near syncope. ResolvedMedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
- 2021-03-14
- 2021-03-16
- 2021-03-17
- 2021-03-26
- 2021-04-02
- 2021-04-09
- 2021-04-18
- 2021-09-10
- 2022-03-12
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-02-19 | Pfizer-BioNTech | |
| 2 | 2021-03-12 | Pfizer-BioNTech |
Free text
Release 5 — days 1–6 daily, dose 2
Systemic reaction (other): Tachycardia and near syncope. Resolved
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SRO | Presyncope | ✓ | ✓ | ✓ |
| SRO | Tachycardia | ✓ | ✓ | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release